Dendritic cell (DC) vaccines induce specific immune responses that can selectively
eliminate target cells. In recent years, many studies have been conducted to explore DC …

Dendritic cell (DC)-based immunotherapy employs the patients' immune system to fight
neoplastic lesions spread over the entire body. This makes it an important therapy option for …

Dendritic cells (DC) are the directors of the immune system, capable of inducing tumour
antigen-specific T-and B-cell responses. As such, they are currently applied in clinical …

Dendritic cells (DCs) are the most potent antigen-presenting cells, and tumor antigen-loaded
DCs (DC-vaccines) can activate tumor-specific cytotoxic T lymphocytes (CTLs) in lymphatic …

Dendritic cells (DCs) are potent antigen-presenting cells that have the ability to stimulate
primary T cell antitumor immune responses in animals and humans. Since the first published …

The use of dendritic cells (DCs) for tumor immunotherapy represents a powerful approach
for harnessing the patient's own immune system to eliminate tumor cells. However …

The US Food and Drug Administration's approval of the first cell‐based immunotherapy has
rejuvenated interest in the field. Early clinical trials have established the ability of dendritic …

Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

The immunotherapy of cancer is predicated on the belief that it is possible to generate a
clinically meaningful antitumor response that provides patient benefit, such as improvement …

Highlights•DC vaccines can induce anti-tumour responses and show clinical benefit.•DC
subsets specialised in Ag cross-presentation are key for anti-tumour responses.•Targeting …